CL2024001542A1 - Métodos para utilizar agonistas de rar gamma para el tratamiento del cáncer - Google Patents
Métodos para utilizar agonistas de rar gamma para el tratamiento del cáncerInfo
- Publication number
- CL2024001542A1 CL2024001542A1 CL2024001542A CL2024001542A CL2024001542A1 CL 2024001542 A1 CL2024001542 A1 CL 2024001542A1 CL 2024001542 A CL2024001542 A CL 2024001542A CL 2024001542 A CL2024001542 A CL 2024001542A CL 2024001542 A1 CL2024001542 A1 CL 2024001542A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- cancer treatment
- rar agonists
- gamma
- rar gamma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282547P | 2021-11-23 | 2021-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001542A1 true CL2024001542A1 (es) | 2024-10-04 |
Family
ID=85706524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001542A CL2024001542A1 (es) | 2021-11-23 | 2024-05-22 | Métodos para utilizar agonistas de rar gamma para el tratamiento del cáncer |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11793835B2 (https=) |
| EP (1) | EP4436574A4 (https=) |
| JP (1) | JP2024541472A (https=) |
| KR (1) | KR20240111779A (https=) |
| CN (1) | CN118574611A (https=) |
| AU (1) | AU2022398628A1 (https=) |
| CA (1) | CA3239689A1 (https=) |
| CL (1) | CL2024001542A1 (https=) |
| IL (1) | IL313052A (https=) |
| MX (1) | MX2024006212A (https=) |
| WO (1) | WO2023097259A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11976021B2 (en) | 2022-06-27 | 2024-05-07 | Io Therapeutics, Inc. | Synthesis of tetrahydronaphthalenols and uses thereof |
| WO2025240479A1 (en) * | 2024-05-14 | 2025-11-20 | Children's National Medical Center | Trained tumor specific t-cell for immunotherapy and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| DE60136477D1 (de) * | 2000-10-02 | 2008-12-18 | Hoffmann La Roche | Retinoide zur behandlung von emphysem |
| WO2005046726A2 (en) * | 2003-11-12 | 2005-05-26 | Allergan, Inc. | Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist |
| US7476673B2 (en) * | 2003-12-30 | 2009-01-13 | Allergan, Inc. | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors |
| BRPI0616454A2 (pt) | 2005-09-30 | 2011-06-21 | Vitae Pharmaceuticals, Inc. | métodos de tratamento de cáncer |
| US20070185055A1 (en) | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
| SG11201810951RA (en) * | 2016-06-10 | 2019-01-30 | Io Therapeutics Inc | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| KR20200029544A (ko) * | 2017-07-13 | 2020-03-18 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물 |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
-
2022
- 2022-11-23 JP JP2024530570A patent/JP2024541472A/ja active Pending
- 2022-11-23 EP EP22899540.3A patent/EP4436574A4/en active Pending
- 2022-11-23 CN CN202280089687.3A patent/CN118574611A/zh active Pending
- 2022-11-23 KR KR1020247020234A patent/KR20240111779A/ko active Pending
- 2022-11-23 CA CA3239689A patent/CA3239689A1/en active Pending
- 2022-11-23 MX MX2024006212A patent/MX2024006212A/es unknown
- 2022-11-23 AU AU2022398628A patent/AU2022398628A1/en active Pending
- 2022-11-23 WO PCT/US2022/080408 patent/WO2023097259A1/en not_active Ceased
- 2022-11-23 IL IL313052A patent/IL313052A/en unknown
- 2022-11-23 US US17/993,528 patent/US11793835B2/en active Active
-
2023
- 2023-10-05 US US18/481,547 patent/US12115193B2/en active Active
-
2024
- 2024-05-22 CL CL2024001542A patent/CL2024001542A1/es unknown
- 2024-10-03 US US18/905,646 patent/US20250026714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4436574A4 (en) | 2025-12-24 |
| WO2023097259A1 (en) | 2023-06-01 |
| US12115193B2 (en) | 2024-10-15 |
| KR20240111779A (ko) | 2024-07-17 |
| US20230095368A1 (en) | 2023-03-30 |
| US20240050479A1 (en) | 2024-02-15 |
| AU2022398628A1 (en) | 2024-06-06 |
| US11793835B2 (en) | 2023-10-24 |
| US20250026714A1 (en) | 2025-01-23 |
| CN118574611A (zh) | 2024-08-30 |
| EP4436574A1 (en) | 2024-10-02 |
| CA3239689A1 (en) | 2023-06-01 |
| MX2024006212A (es) | 2024-07-09 |
| JP2024541472A (ja) | 2024-11-08 |
| IL313052A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001542A1 (es) | Métodos para utilizar agonistas de rar gamma para el tratamiento del cáncer | |
| MX2024002838A (es) | Metodos para tratar trastornos usando inhibidores de csf1r. | |
| MX2019005617A (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
| MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
| MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
| CL2018001108A1 (es) | Composiciones y métodos para transducción de tumores | |
| MX388015B (es) | Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer. | |
| CL2019002461A1 (es) | Arn terapéutico. | |
| AR112072A1 (es) | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario | |
| CR20170036A (es) | Inhibidores de la proteína quinasa c y métodos de su uso | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CL2021001027A1 (es) | Inhibidores selectivos de rgmc y el uso de los mismos | |
| MX2020005634A (es) | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| MX2016010080A (es) | Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer. | |
| CO2018005678A2 (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación | |
| MX384175B (es) | Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva. | |
| MX2020003192A (es) | Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1. | |
| MX385372B (es) | Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos | |
| DOP2023000155A (es) | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina |